Atopic dermatitis differential diagnosis: Difference between revisions
Jump to navigation
Jump to search
Line 14: | Line 14: | ||
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Inherited | ! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Inherited | ||
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquired | ! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Acquired | ||
! colspan=" | ! colspan="11" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Clinical manifestations | ||
! colspan="4" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings | ! colspan="4" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings | ||
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings | ! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings | ||
Line 21: | Line 21: | ||
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated factors | ! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated factors | ||
! colspan="6" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Symptoms | ! colspan="6" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Symptoms | ||
! colspan=" | ! colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical examination | ||
|- | |- | ||
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings | ! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings | ||
Line 30: | Line 30: | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bleeding | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bleeding | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Tenderness | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Tenderness | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other | ||
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |CBC | ! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |CBC | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Serum IgE | ||
|- | |- | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Single/ | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Single/ | ||
Line 69: | Line 68: | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 87: | Line 85: | ||
(Eosinophilia) | (Eosinophilia) | ||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | ↑ | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Epidermal psoriasiform [[hyperplasia]] | * Epidermal psoriasiform [[hyperplasia]] | ||
Line 116: | Line 114: | ||
| align="center" style="background:#F5F5F5;" |– | | align="center" style="background:#F5F5F5;" |– | ||
| align="center" style="background:#F5F5F5;" |– | | align="center" style="background:#F5F5F5;" |– | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 145: | Line 142: | ||
| align="center" style="background:#F5F5F5;" |– | | align="center" style="background:#F5F5F5;" |– | ||
| align="center" style="background:#F5F5F5;" |– | | align="center" style="background:#F5F5F5;" |– | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 176: | Line 172: | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" |– | | align="center" style="background:#F5F5F5;" |– | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 217: | Line 212: | ||
(pinpoint bleeding) | (pinpoint bleeding) | ||
| align="center" style="background:#F5F5F5;" | _ | | align="center" style="background:#F5F5F5;" | _ | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 245: | Line 239: | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 287: | Line 280: | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 324: | Line 316: | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 364: | Line 355: | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 371: | Line 361: | ||
** "Bamboo hair" or "ball and socket deformity" of hair and eyebrows | ** "Bamboo hair" or "ball and socket deformity" of hair and eyebrows | ||
** Nodes along the hair shaft | ** Nodes along the hair shaft | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" |Nl to ↑ | ||
(Eosinophilia) | |||
| align="center" style="background:#F5F5F5;" | Nl | | align="center" style="background:#F5F5F5;" | Nl | ||
| align="center" style="background:#F5F5F5;" | ↑ | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* psoriasiform hyperplasia | * psoriasiform hyperplasia | ||
Line 401: | Line 391: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bleeding | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bleeding | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Tenderness | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Tenderness | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other | ||
Line 412: | Line 401: | ||
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Infection | ! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Infection | ||
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Dermatophyte|Dermatophytes]] | ! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Dermatophyte|Dermatophytes]] | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 453: | Line 441: | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | If molluscum contagiosum is acquired as sexually transmitted disease, it involves, groin and genital region. | | align="center" style="background:#F5F5F5;" | If molluscum contagiosum is acquired as sexually transmitted disease, it involves, groin and genital region. | ||
Line 478: | Line 465: | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | +++ | | align="center" style="background:#F5F5F5;" | +++ | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 503: | Line 489: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bleeding | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bleeding | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Tenderness | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Tenderness | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other | ||
Line 532: | Line 517: | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 574: | Line 558: | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | Infants can present with petechiae, prolonged bleeding from umbilicus or circumcision, purpura, hematemesis, melena, epistaxis, hematuria or unusal bruising | | align="center" style="background:#F5F5F5;" | Infants can present with petechiae, prolonged bleeding from umbilicus or circumcision, purpura, hematemesis, melena, epistaxis, hematuria or unusal bruising | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" |Nl to ↑ | ||
(Eosinophilia) | |||
| align="center" style="background:#F5F5F5;" | Thrombocytopenia | | align="center" style="background:#F5F5F5;" | Thrombocytopenia | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | ↑ | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* [[Hyperkeratosis]] | * [[Hyperkeratosis]] | ||
Line 622: | Line 607: | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 629: | Line 613: | ||
* High-arched oral palate | * High-arched oral palate | ||
* Hyperextensible joints | * Hyperextensible joints | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" |Nl to ↑ | ||
(Eosinophilia) | |||
| align="center" style="background:#F5F5F5;" |Nl | | align="center" style="background:#F5F5F5;" |Nl | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | ↑ | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Eosinophil-rich infiltration around the hair follicles | * Eosinophil-rich infiltration around the hair follicles | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* | * | ||
|- | |- | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Malignancy | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Malignancy | ||
Line 663: | Line 648: | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | – | | align="center" style="background:#F5F5F5;" | – | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
Line 702: | Line 686: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bleeding | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Bleeding | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Fever | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Tenderness | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Tenderness | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other |
Revision as of 14:20, 25 October 2018
Atopic dermatitis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Atopic dermatitis differential diagnosis On the Web |
American Roentgen Ray Society Images of Atopic dermatitis differential diagnosis |
Risk calculators and risk factors forAtopic dermatitis differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Differentiating Atopic Dermatitis from other Diseases
Category | Diseases | Etiology | Inherited | Acquired | Clinical manifestations | Para-clinical findings | Additional findings | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Demography | Associated factors | Symptoms | Physical examination | |||||||||||||||||
Lab Findings | Histopathology | |||||||||||||||||||
Appearance | Itching | Bleeding | Fever | Tenderness | Other | CBC | Serum IgE | |||||||||||||
Single/
Multiple |
Rash | Involved areas | Pustule | WBC | Platelets | |||||||||||||||
Skin disorders | Atopic dermatitis |
|
+ | + |
|
|
Multiple |
|
– | + | – | – | – |
|
Nl to ↑
(Eosinophilia) |
Nl | ↑ |
|
| |
Allergic contact dermatitis[1] |
|
– | + | Any |
|
May be multiple after 1-2 days of exposure | Erythematous well-demarcated papules | Surrounding the area in contact with the offending agent | – | + | – | – | + |
|
Nl to ↑
(Eosinophilia) |
Nl | Nl | NA |
| |
Irritant contact dermatitis[2] |
|
– | + | Any, more occupational exposure |
|
Usually single immediately after the exposure | Well-demarcated red patch with a glazed surface | Any area in contact with the irritant | – | + | – | – | + |
|
Nl | Nl | Nl |
|
| |
Seborrheic dermatitis |
|
– | + | Any, onset during the 1st days or weeks of life |
|
Greasy scaling on a yellow-red base | Scalp, axilla, and diaper area | – | ||||||||||||
Psoriasis |
|
+ | + | Any, 2 peaks of onset 30-39 years and 50-59 years |
|
Multiple | Well-circumscribed, pink papules and symmetrically distributed cutaneous plaques with silvery scales |
|
+ | + | +
Auspitz sign (pinpoint bleeding) |
_ | + | |||||||
Lichen simplex [3]chronicus |
|
– | + | Any, peak at 30-50 years of age |
|
Multiple | Lichenified and erythematous, pruritic exudative plaque, and excoriations | Scalp, head, neck, hands, arms, and genitals areas | – | + | – | – | – |
|
Nl | Nl | Nl |
|
| |
Ichthyosis vulgaris[4] |
|
+ | + | Usually in infancy |
|
Multiple |
|
|
– | – | – | – | – |
|
Nl | Nl | Nl |
|
| |
Nummular dermatitis (discoid eczema) | Unknown | – | + | Any, two peaks, 6th-7th decade of life in males and 2nd-3rd decade of life in females |
|
Multiple | Nl |
|
– | + | – | – | – |
|
Nl | Nl | Nl |
|
| |
Netherton's syndrome[5] | Autosomal recessive mutations in the serine protease inhibitor of Kazal type 5 gene (SPINK5), encoding LEKTI, a serine protease inhibitor | + | – | Affects neonates |
|
Multiple |
|
|
+ | + | – | – | – |
|
Nl to ↑
(Eosinophilia) |
Nl | ↑ |
|
| |
Diseases | Etiology | Inherited | Acquired | Demography | Associated factors | Single/
Multiple |
Rash | Involved areas | Pustule | Itching | Bleeding | Fever | Tenderness | Other | WBC | Platelets | ESR/CRP | Histopathology | Additional findings | |
Infection | Dermatophytes | |||||||||||||||||||
Molluscum contagiosum | Molluscum contagiosum virus inoculation through direct skin contact | – | + | Any, peak among children >5 years of age and young adults |
|
Multiple |
|
|
– | + | – | – | – | If molluscum contagiosum is acquired as sexually transmitted disease, it involves, groin and genital region. | Nl | Nl | Nl |
|
mMlluscum contagiosum
lesions on the eyelid may lead to follicular or papillary conjunctivitis . | |
Scabies |
|
Multiple | Erythematous papular lesions | Flexor wrists, finger webs and genitalia | +++ | |||||||||||||||
Diseases | Etiology | Inherited | Acquired | Demography | Associated factors | Single/
Multiple |
Rash | Involved areas | Pustule | Itching | Bleeding | Fever | Tenderness | Other | WBC | Platelets | ESR/CRP | Histopathology | Additional findings | |
Immunologic disorders | Dermatitis herpetiformis[6] | Autoimmune disorder as a result of gluten sensitivity leading to the formation of IgA antibodies | – | + | Any, mean age of disease onset is 2nd-4th decade |
|
Multiple |
|
|
– | + | – | – | – |
|
Nl | Nl | Nl |
|
|
Immune deficiency | Wiskott-Aldrich syndrome[7] |
|
+ | – | Seen almost exclusively in males in infancy |
|
Multiple |
|
Rash can involve lesions located at the same areas of classical atopic dermatitis:
extensor surfaces of extremities and cheeks or scalp |
– | + | + | – | – | Infants can present with petechiae, prolonged bleeding from umbilicus or circumcision, purpura, hematemesis, melena, epistaxis, hematuria or unusal bruising | Nl to ↑
(Eosinophilia) |
Thrombocytopenia | ↑ |
|
|
Hyper-IgE syndrome[8] |
|
+ | – | Rare, begin in infancy |
|
Multiple |
|
|
+ | + | – | – | – |
|
Nl to ↑
(Eosinophilia) |
Nl | ↑ |
|
| |
Malignancy | Mycosis fungoides | Clonal expansion of CD4+ memory T cells (CD45RO+) | – | + | Mean age is 55- 60 years |
|
Multiple |
|
|
– | + | – | – | – |
|
Nl | Nl | Nl |
|
|
Category | Diseases | Etiology | Inherited | Acquired | Demography | Associated factors | Single/
Multiple |
Rash | Involved areas | Pustule | Itching | Bleeding | Fever | Tenderness | Other | WBC | Platelets | ESR/CRP | Histopathology | Additional findings |
References
- ↑ Nosbaum A, Vocanson M, Rozieres A, Hennino A, Nicolas JF (2009). "Allergic and irritant contact dermatitis". Eur J Dermatol. 19 (4): 325–32. doi:10.1684/ejd.2009.0686. PMID 19447733.
- ↑ Bains SN, Nash P, Fonacier L (October 2018). "Irritant Contact Dermatitis". Clin Rev Allergy Immunol. doi:10.1007/s12016-018-8713-0. PMID 30293200.
- ↑ Voicu C, Tebeica T, Zanardelli M, Mangarov H, Lotti T, Wollina U, Lotti J, França K, Batashki A, Tchernev G (July 2017). "Lichen Simplex Chronicus as an Essential Part of the Dermatologic Masquerade". Open Access Maced J Med Sci. 5 (4): 556–557. doi:10.3889/oamjms.2017.133. PMC 5535688. PMID 28785363.
- ↑ Thyssen JP, Godoy-Gijon E, Elias PM (June 2013). "Ichthyosis vulgaris: the filaggrin mutation disease". Br. J. Dermatol. 168 (6): 1155–66. doi:10.1111/bjd.12219. PMID 23301728.
- ↑ Chavanas S, Bodemer C, Rochat A, Hamel-Teillac D, Ali M, Irvine AD, Bonafé JL, Wilkinson J, Taïeb A, Barrandon Y, Harper JI, de Prost Y, Hovnanian A (June 2000). "Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome". Nat. Genet. 25 (2): 141–2. doi:10.1038/75977. PMID 10835624.
- ↑ Kárpáti S (2012). "Dermatitis herpetiformis". Clin. Dermatol. 30 (1): 56–9. doi:10.1016/j.clindermatol.2011.03.010. PMID 22137227.
- ↑ Buchbinder D, Nugent DJ, Fillipovich AH (2014). "Wiskott-Aldrich syndrome: diagnosis, current management, and emerging treatments". Appl Clin Genet. 7: 55–66. doi:10.2147/TACG.S58444. PMC 4012343. PMID 24817816.
- ↑ Mogensen TH (April 2013). "STAT3 and the Hyper-IgE syndrome: Clinical presentation, genetic origin, pathogenesis, novel findings and remaining uncertainties". JAKSTAT. 2 (2): e23435. doi:10.4161/jkst.23435. PMC 3710320. PMID 24058807.